Bristol-Myers Squibb (BMY) Announces Receipt of EC Approval for Daklinza in Certain HCV Genotypes
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved Daklinza for the treatment of chronic hepatitis C ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
